Fearing Second Offer Failure, Stada Management Appeals To Shareholders
Executive Summary
Stada's management is scared an offer from two private-equity suitors will fail a second time due to shareholder inactivity or reluctance to accept the deal before its Aug 16 deadline.
You may also be interested in...
Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line
Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.
Cinven's M&A Ambitions Over Stada Under Scrutiny, Advent and Others Circle
By stalking Stada, Cinven seems to be planning to use the German generics group as a base that can support later carve-outs of mature and undervalued products from larger pharma companies - but it faces a rival bidder in Advent, and more suitors could yet appear.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.